UNSPSC 85505187: Dilation of left axillary artery with drug-eluting intraluminal device, percutaneous endoscopic approach

This classification denotes the group of activities that yields a surgical intervention or procedure to dilation of left axillary artery with drug-eluting intraluminal device, percutaneous endoscopic approach. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 037644Z

UNSPSC 85505187 Dilation of left axillary artery with drug-eluting intraluminal device, percutaneous endoscopic approach is a Commodity code that does not align with the recent state and local contract opportunities posted under it. The code nominally describes a specific vascular surgical procedure, yet the six recent solicitations tagged with this code across state and local jurisdictions involve occupational medical surveillance, independent disability medical evaluations, pharmacy benefit management, temporary health professional staffing, surgical benefit carve-out programs, and emergency services for youth in custody — none of which involve coronary or peripheral vascular intervention. This represents a classification mismatch in the source data rather than legitimate procurement activity under the code's intended scope.

State and local issuers appear to have used this code incorrectly or as a placeholder across geographically dispersed jurisdictions including Arizona (City of Phoenix), California (City of Long Beach, Collier County, County of Santa Clara), Washington (Washington State Department of Transportation), and Texas (Harris County). The absence of any actual vascular intervention procurement suggests the code sees little relevant recent activity for firms seeking to pursue contracts in this medical device or procedure category. Business development professionals monitoring this code should verify current UNSPSC tagging practices with target jurisdictions, as the recent opportunities do not reflect genuine demand in the vascular intervention market.